'Elderly' patients with newly diagnosed glioblastoma deserve optimal care

Journal of Neuro-Oncology

Volumn 113, Issue 2, 2013, Pages 343-344

  Holdhoff, Matthias ^a   Rosner, Gary L ^a   Alcorn, Sara ^a   Grossman, Stuart A ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TEMOZOLOMIDE;

ADULT; AGED; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; ELDERLY CARE; FOLLOW UP; GLIOBLASTOMA; HEALTH CARE QUALITY; HUMAN; LETTER; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; RADIATION DOSE; SURVIVAL TIME; BRAIN NEOPLASMS; CHEMORADIOTHERAPY; STANDARDS;

AGED; BRAIN NEOPLASMS; CHEMORADIOTHERAPY; GLIOBLASTOMA; HUMANS; QUALITY OF HEALTH CARE;

EID: 84879118353     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-013-1113-7     Document Type: Letter

References (6)

1. Wick W, Platten M, Meisner C, Felsberg J, Tabatabai G, Simon M, Nikkhah G, Papsdorf K, Steinbach JP, Sabel M et al (2012) Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 13:707-715. doi: 10.1016/S1470-2045(12)70164-X
2. Malmstrom A, Gronberg BH, Marosi C, Stupp R, Frappaz D, Schultz H, Abacioglu U, Tavelin B, Lhermitte B, Hegi ME et al (2012) Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol 13:916-926. doi: 10.1016/S1470-2045(12)70265-6
3. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996. doi: 10.1056/NEJMoa043330
4. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459-466. doi: 10.1016/S1470-2045(09)70025-7
5. Dolecek TA, Propp JM, Stroup NE, Kruchko C (2012) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. Neuro Oncol 14(Suppl 5):v1-v49. doi: 10.1093/neuonc/nos218
6. Yovino S, Grossman SA (2011) Treatment of glioblastoma in "elderly" patients. Curr Treat Options Oncol 12:253-262. doi: 10.1007/s11864-011-0158-0